Last checked at 
LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Thursday said it is unable to explain the recent movement in its share price.
Faron noted Thursday's 43% share price rise, and said it knows of no operational or corporate reason for the move.
The firm said it continues to progress both its key products, Clevegen and Traumakine. As already reported, Faron said it has seen encouraging early observations in the Matins trial.
Faron said it is currently engaged in partnering discussions with "several parties" and said it hopes for a "positive outcome" from these negotiations during 2019.
